Midazolam (0.1-0.2 mg/kg/hr) and morphine (2 mg/hr) were given by carefully regulated continuous intravenous infusions to thirty patients who required sedation, analgesia and ventilation for between twelve and twenty-four hours in the Intensive Care Unit. The midazolam and morphine infusions were stopped at the end of the period of sedation required and the efficacy of placebo or ./lumazenil in reversing the sedative effects of midazolam was compared in this double-blind randomised parallel group study.
ability to assess the clinical status of the patient, delay in weaning from a ventilator and, in the self-ventilating patient, the potential to maintain an adequate level of respiratory function.
The benzodiazepines exert the depressant effect on neuronal activity by selective enhancement of inhibitory GABA-ergic synaptic transmissions to the central nervous system 9 ,IO following interaction between the benzodiazepine and specific neuronal membrane receptors. II , 12 The imidazodiazepine flumazenil (Anexate) was first characterised in 1979 and was found to be a specific benzodiazepine antagonist with minimal intrinsic activity. It is a potent competitive inhibitor of the specific binding of the benzodiazepine at the receptor. 13 Clinical trials have demonstrated the efficacy of flumazenil in rapidly reversing the central depressant effects of a benzodiazepine after its use as a supplement during general anaesthesia,14-16 as a supplement to local or regional anaesthesia, 17, 18 or when the benzodiazepine has been used as the sole agent for short periods of sedation 19 or for longer periods of sedation in an intensive care environment. 20, 21 The aim of this study was to evaluate the efficacy of flumazenil in reversing the central effects of midazolam when the latter has been used to sedate patients for periods of between twelve and twenty-four hours.
METHODS
Thirty patients of either sex between the ages of 16 and 80 years in the Intensive Care U nit requiring sedation, analgesia and mechanical ventilation for a minimum period of twelve hours were studied in this doubleblind randomised parallel group study. Approval for the study was obtained from the District Ethical Committee and informed consent was obtained from suitable patients or their next of kin.
When suitable patients were admitted to the Intensive Care Unit, bolus doses of morphine were given according to individual requirements to ensure they received adequate analgesia. The patients were assessed and given a severity score according to a modified Apache 11 scoring system. Severely ill patients were those scoring 20 or more. The condition leading to the admission of each patient, any concurrent disease processes and all medications given during the hour prior to admission into the trial were recorded.
On admission to the trial, infusions of midazolam and morphine were started. The infusion of midazolam was started at a rate of between 0.1 and 0.2 mg/kg/hr and was thereafter adjusted to maintain sedation at the desired level; this was defined as a patient who was cooperative, orientated and tranquil when aroused but who would sleep when not aroused ( Table 1 ). The infusion of morphine was started at a rate of 2 mg/hr and as far as possible this rate was maintained during the period of sedation. If analgesia was considered inadequate or prior to any painful procedures the rate of infusion of morphine was temporarily increased or a bolus of morphine was given.
No neuromuscular blocking agents were administered during the trial period and all concurrent therapy was administered and adjusted as required. A record was kept of all drugs given.
All patients were ventilated with oxygenenriched air, the inspired oxygen concentration and pattern of ventilation being adjusted to maintain satisfactory blood gases.
At the end of the period of sedation, the midazolam and morphine infusions were stopped. The patients were then allocated to a prearranged randomised schedule to receive either an infusion offlumazenil (0.1 mg/ml) or placebo (inert carrier). The rate of infusion was initially 4 ml/hr and thereafter adjusted according to the response.
During the study the following assessments were performed.
Sedation:
(a) The total doses of midazolam and of morphine given and the duration of these infusions were recorded. (b) During the post sedation period, responsiveness was assessed at 5, 15, 30, 60 and 120 minutes after the infusion of flumazenil or placebo had been started. The degree of sedation based on a scale of 0-3 (Table 2 ) and the ability to obey a o I 2 3 imitation only execution of order simple command based on the response when ordered to raise an arm on a scale of 0-2 (Table 3) were recorded.
Weaning and extubation:
The times taken to wean the patient from the ventilation and to extubation after the midazolam infusion had been stopped were recorded.
Adverse events:
All unexpected or untoward events occurring during the trial period were recorded.
Statistical methods:
The unpaired Student's t test was used to compare the difference in weight, duration of midazolam infusion and duration of adequate sedation for the two treatment groups. All other results were compared using the Mann Whitney U test.
RESULTS

Demographic data:
Thirty patients were recruited for the study, fifteen received flumazenil and fifteen placebo by infusion after the infusion of midazolam had been stopped. There were no significant differences between the ages, weights or sex distribution between the treatment groups (Table 4 ). There were also no statistically significant differences between the two groups when considering the presence of concurrent illness, reason for admission to the Intensive Care Unit or the median severity scores ( Table 5 ). 
Sedation:
(a) During the midazolam infusion, but prior to the administration of flumazenil or placebo. There were no statistically significant differences between the groups during the period of sedation. The overall mean doses of midazolam (mg/kg/hr), the durations of the midazolam infusion (hr) and the median duration of adequate sedation (hr) in the two groups are shown above in Table 6 . The overall mean dose of morphine (mg/kg) was the same in each group.
(b) After treatment with placebo or flumazenil. The median sedation score and the median score related to an assessment of the patients' ability to obey a simple command at the time the midazolam infusion was stopped and at 5, 15, 30, 60 and 120 minutes after infusion of either flumazenil or placebo had been started are shown in Figures 1 and 2 respectively. The results show a statistically significant difference (P < 0.05) between the treatment groups indicating that patients who received flumazenil were less sedated than those given placebo as early as five minutes after the infusion of flumazenil had commenced. The statistically significant difference was still present after two hours (Figure 1) . In assessing the ability to obey a simple command, a statistically significant difference between the treatment groups at 15, 30 and 60 minutes indicated that patients receiving flumazenil were more co-operative than those receiving placebo. By 120 minutes, there was no difference between the two treatment groups. 
Weaning and extubation:
The mean times taken from the cessation of sedation to the point of weaning from ventilation and to extubation are shown in Table 7 . The results show a statistically significant difference (P < 0.05) between the treatment groups. It was considered appropriate on clinical grounds that six patients in the study (three from each treatment group) should be offered ventilatory support for a further 24 hours. Sedation and analgesia were re-established in those patients using midazolam and morphine without any problems.
Adverse events:
None was noted during the trial period in either group.
DISCUSSION
The combination of a benzodiazepine and an opioid has been the standard sedative regime in many Intensive Care Units for some time. 22 ,23 The benzodiazepines have no specific analgesia activity, therefore the need to supplement these sedative agents with an analgesic is essential. The opioids have both analgesic and sedative properties. If they are used rationally and in low doses, they have no effect on cardiovascular stability24 though they may cause some respiratory depression in the self-ventilating patient. 25 Diazepam was the most commonly used benzodiazepine before the introduction of midazolam in 1982. Midazolam with its rapid onset of action, elimination half-life of 90 minutes, 8 and metabolites with an elimination half-life considerably shorter than that of the parent drug 26 is proving a much more satisfactory sedative than diazepam which has an elimination half-life of 24-72 hours and two active metabolites, one, desmethyldiazepam, having a longer elimination half-life than diazepam. 27 Many physiological and pathological factors often found in intensive care patients may result in a longer elimination half-life than would normally be expected in healthy individuals. Reports of a prolonged duration of action of midazolam in patients supported by mechanical ventilation,28 with impaired hepatic function 29 and in septic shock 30 have appeared in the literature. It has also been suggested that approximately six per cent of the population are poor metabolisers of midazolam. 31 The need, therefore, to define the desired level of sedation and to regulate the rate of administration of midazolam to maintain this throughout the treatment period is essential.
In this study, midazolam proved to be a satisfactory sedative agent when administered by a continuous intravenous infusion. The mean dose of midazolam given was 0.094 mg/kg/hr and the patients were considered to have been adequately sedated for 95.3% of the time.
Ten patients, five in each treatment group, with Apache 11 scores greater than 20 required less midazolam to maintain the desired level of sedation than those with a score less than 20. The mean dose of midazolam given in this group was 0.081 mg/kg/hr. The lower dose requirements presumably reflected a prolonged elimination half-life associated with more severe pathological and physiological changes in the group of patients.
Flumazenil has a rapid onset of action and an elimination half-life of 60 minutes 32 ,33 in healthy individuals. The duration of action of flumazenil is influenced by several factors, chief of which are the dose of flumazenil, the total dose and elimination half-life of the agonist given and the time elapsed since the benzodiazepine agonist was given. The pharmacokinetic profile of midazolam indicates that flumazenil should be more effective in reversing the central effects of midazolam than other benzodiazepines. The elimination half-life of flumazenil is shorter than that of midozalam, and therefore the response to a single dose of flumazenil may only be temporary, after which resedation may occur. It has also been demonstrated that the rapid administration of flumazenil can precipitate an acute anxiety state in the patient. 16 In this study, the trial material was administered by a slow intravenous infusion initially at the rate of 4 mllhr. The rate was adjusted according to the response and was maintained for three hours. There was a statistically significant difference between the treatment groups as early as five minutes after the infusion of midazolam had been stopped Anaesthesia and Intensive Care, Vol, 18, No. 1, February, 1990 and the trial material started (P < 0.05) as indicated by the fact that patients receiving flumazenil were less sedated and more co-operative than those who had received placebo. The transition from the sedated to the aroused state was slow enough, even in those patients who received flumazenil, to allow the medical and nursing staff to support the patient during this period. As a result no patient complained of any untoward anxiety. There were no problems of resedation noted in patients who received flumazenil.
The specificity of flumazenil also proved beneficial, all patients remaining reasonably comfortable with adequate analgesia during the immediate post-sedation period.
When comparing the treatment groups there was a significant difference (P < 0.05) in the time taken to wean the patients from ventilation and subsequently to extubate the patients. The patients who received flumazenil were weaned and extubated much earlier than those who received placebo. The patients with Apache 11 scores greater than 20 behaved in a similar way to those with a score ofless than 20. The elimination offlumazenil, an imidazobenzodiazepine, is presumably affected by the same factors influencing the elimination of midazolam. Three patients in each treatment group after reassessment were considered in need of further ventilatory support. No problems were experienced in re-establishing the desired levels of sedation and analgesia with infusions of midazolam and morphine. The short elimination half-life of flumazenil proved beneficial in this situation.
In conclusion, this paper shows that midazolam given by a continuous intravenous infusion is an effective sedative agent for patients in an intensive care unit. The paper also shows that flumazenil provides the clinician with a safe and effective method of reversing the central depressant effect of midazolam. The flumazenil was given by a continuous intravenous infusion that was maintained for three hours. The patients receiving flumazenil were more co-operative and responsive, improvements that facilitated weaning from ventilation, a return to spontaneous ventilation and, therefore, earlier extubation.
The short elimination half-life of flumazenil allowed for easy re sedation with midazolam in those patients who, after reassessment, required further ventilatory support.
